ORTX News and Press, Orchard Therapeutics plc From 06/26/23

2023-06-26 14:29:18 ET Orchard Therapeutics ( NASDAQ: ORTX ) said that it has closed on a second $34M financing as part of a larger agreement that could garner the company up to $188M if certain regulatory milestones are met. The second financing included the issuance of 4.25M A...

Funding from second closing extends cash runway to mid-2025 to advance the company’s HSC gene therapy portfolio through several potential value-creating milestones OTL-200 (MLD) BLA submission initiated and on track for completion in mid-2023 with potential for U.S. approval in t...

BOSTON and LONDON, May 24, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will make a virtual presentation at Stifel’s Inaugural Genetic Medicines Day on Tuesday, May 30, 2023 at 5:00 p.m. EDT. A webcast of...

2023-05-19 09:54:47 ET British biotech Orchard Therapeutics ( NASDAQ: ORTX ) on Friday announced new clinical data for its hematopoietic stem cell (HSC) gene therapy candidates in metabolic disorders Mucopolysaccharidosis type I (MPS-I) and Mucopolysaccharidosis type IIIA (MPS-IIIA)...

New OTL-203 proof-of-concept data demonstrate extensive metabolic correction in the skeletal system of patients with MPS-IH including normal growth rates, improvement in joint function and progressive acquisition of motor skills Updated OTL-201 data from ongoing proof-of-concept study i...

Preclinical proof-of-concept data show the therapeutic potential of OTL-104 for NOD2 Crohn’s disease, a severe and treatment-refractory form of the disease In vivo data demonstrate the development of CAR-Treg cells from genetically engineered HSCs as a potential one-time treatmen...

2023-05-15 10:03:03 ET Orchard Therapeutics press release ( NASDAQ: ORTX ): Q1 GAAP EPS of -$0.12. Revenue of $1.23M (-77.7% Y/Y). For further details see: Orchard Therapeutics GAAP EPS of -$0.12, revenue of $1.23M

OTL-200 Biologics License Application (BLA) submission completion anticipated in mid-2023 Libmeldy revenue and commercial patients treated expected to grow year-over-year in 2023 New clinical data in MPS-I and MPS-IIIA and pre-clinical data in genetic subsets of frontotemporal d...

Six presentations showcase the differentiated profile and broad applicability of the company’s HSC gene therapy platform Oral presentations in MPS-IH and MPS-IIIA and the progranulin form of frontotemporal dementia highlight leadership in neurometabolic and CNS diseases P...

2023-04-24 17:38:49 ET Summary Shares have lost a third of their value over the past year. HSC-based gene therapy Libmeldy is approved in the EU for MLD with a ~$3.5M price tag. Incidence could be higher than initial estimates. Cash position was bolstered with March financing,...